<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sasagawa H</submitter><funding>Japan Agency for Medical Research and Development</funding><pagination>pkaf118</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12803783</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>BRCA1 pathogenic variants are associated with a lower risk of developing prostate cancer than BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanalyzed the impact of BRCA1 pathogenic variants on aggressiveness using 11 300 prostate cancer patients, adjusting for age and area. The proportion of aggressive prostate cancer was higher in BRCA1 carriers (86.7%) than in noncarriers (61.1%) (odds ratio = 4.87; 95% confidence interval = 1.05 to 22.60). The proportion of high prostate-specific antigen levels was higher in BRCA1 carriers (66.7%) than in noncarriers (27.9%) (P = 7.61 × 10-3). BRCA1 carriers had a worse tendency than noncarriers for T classification (T3-4: BRCA1, 36.4%; noncarriers, 23.2%) and Gleason score (GS8-10: BR</pubmed_abstract><journal>JNCI cancer spectrum</journal><pubmed_title>Revisiting the impact of BRCA1 pathogenic variants on the aggressiveness of prostate cancer.</pubmed_title><pmcid>PMC12803783</pmcid><funding_grant_id>JP19kk0305010</funding_grant_id><funding_grant_id>JP18km0605001</funding_grant_id><funding_grant_id>JP23tm0624002</funding_grant_id><funding_grant_id>JP23ck0106805</funding_grant_id><pubmed_authors>Narita S</pubmed_authors><pubmed_authors>Sasagawa H</pubmed_authors><pubmed_authors>Momozawa Y</pubmed_authors><pubmed_authors>Matsuda K</pubmed_authors><pubmed_authors>Kosaka T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Revisiting the impact of BRCA1 pathogenic variants on the aggressiveness of prostate cancer.</name><description>BRCA1 pathogenic variants are associated with a lower risk of developing prostate cancer than BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanalyzed the impact of BRCA1 pathogenic variants on aggressiveness using 11 300 prostate cancer patients, adjusting for age and area. The proportion of aggressive prostate cancer was higher in BRCA1 carriers (86.7%) than in noncarriers (61.1%) (odds ratio = 4.87; 95% confidence interval = 1.05 to 22.60). The proportion of high prostate-specific antigen levels was higher in BRCA1 carriers (66.7%) than in noncarriers (27.9%) (P = 7.61 × 10-3). BRCA1 carriers had a worse tendency than noncarriers for T classification (T3-4: BRCA1, 36.4%; noncarriers, 23.2%) and Gleason score (GS8-10: BR</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-06T15:17:24.996Z</modification><creation>2026-06-01T03:11:01.377Z</creation></dates><accession>S-EPMC12803783</accession><cross_references><pubmed>41423785</pubmed><doi>10.1093/jncics/pkaf118</doi></cross_references></HashMap>